Clinical Trial

A Clinical Study Exploring CT1190B in the Treatment of Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

Study acronym: CT1190B
Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated February 12, 2025 (before its estimated September 30, 2025 completion). Its status may not reflect the trial's current state.
Summary
A Clinical Study to Investigate the Safety, Efficacy, and Cellular Metabolism of CT1190B CAR-T Cell therapy, in Patients with Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma.
Trial Details
NCT Number NCT06822868
Lead Sponsor Kai Hu
Conditions B-Cell Non-Hodgkin Lymphoma
Enrollment 24 participants
Start Date 2025-02-10
Primary Completion 2025-09-30 (estimated)
Study Completion 2026-09-30 (estimated)
Updated on ClinicalTrials.gov 2025-02-12